PELUCCHI, SARA
 Distribuzione geografica
Continente #
NA - Nord America 8.526
AS - Asia 4.197
EU - Europa 3.718
SA - Sud America 711
AF - Africa 100
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 1
Totale 17.264
Nazione #
US - Stati Uniti d'America 8.054
SG - Singapore 1.504
CN - Cina 977
IT - Italia 796
DE - Germania 570
BR - Brasile 537
HK - Hong Kong 514
RU - Federazione Russa 497
VN - Vietnam 485
CA - Canada 413
SE - Svezia 410
IE - Irlanda 331
UA - Ucraina 231
GB - Regno Unito 226
FR - Francia 184
IN - India 144
FI - Finlandia 118
BD - Bangladesh 107
KR - Corea 68
AT - Austria 66
TR - Turchia 62
NL - Olanda 58
AR - Argentina 54
IQ - Iraq 52
ES - Italia 46
ID - Indonesia 44
PK - Pakistan 39
JP - Giappone 36
MX - Messico 36
BE - Belgio 35
DK - Danimarca 34
ZA - Sudafrica 33
CO - Colombia 29
PL - Polonia 28
PH - Filippine 27
EC - Ecuador 26
VE - Venezuela 26
UZ - Uzbekistan 23
SA - Arabia Saudita 22
LT - Lituania 17
PY - Paraguay 13
MA - Marocco 12
CH - Svizzera 11
ET - Etiopia 11
MY - Malesia 10
AU - Australia 9
IR - Iran 9
CL - Cile 8
CZ - Repubblica Ceca 8
EG - Egitto 8
KE - Kenya 8
NP - Nepal 8
JO - Giordania 7
KG - Kirghizistan 7
PE - Perù 7
RO - Romania 7
TN - Tunisia 7
BG - Bulgaria 6
HU - Ungheria 6
TH - Thailandia 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
KZ - Kazakistan 5
PT - Portogallo 5
RS - Serbia 5
UY - Uruguay 5
BO - Bolivia 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
MT - Malta 4
NG - Nigeria 4
OM - Oman 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
GR - Grecia 3
HR - Croazia 3
IL - Israele 3
JM - Giamaica 3
LB - Libano 3
PA - Panama 3
SV - El Salvador 3
TW - Taiwan 3
AL - Albania 2
CG - Congo 2
CY - Cipro 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
TG - Togo 2
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BM - Bermuda 1
BY - Bielorussia 1
EU - Europa 1
GA - Gabon 1
Totale 17.241
Città #
Ann Arbor 1.285
Singapore 927
Ashburn 826
Woodbridge 556
San Jose 529
Hong Kong 492
Fairfield 446
Houston 389
Chandler 388
Frankfurt am Main 348
Dublin 318
Toronto 287
Milan 256
Wilmington 256
Jacksonville 236
New York 197
Dearborn 186
Seattle 177
Cambridge 152
Los Angeles 152
Ho Chi Minh City 148
Santa Clara 146
Beijing 145
Princeton 109
Chicago 108
The Dalles 108
Hanoi 103
Nanjing 95
Dallas 87
Hefei 84
Shanghai 72
Buffalo 71
Lauterbourg 63
Seoul 61
São Paulo 60
Vienna 58
Boardman 57
Rome 55
Lawrence 51
Munich 47
Altamura 45
Council Bluffs 45
Orem 44
Moscow 43
Helsinki 41
Lachine 40
San Diego 36
Brussels 31
Nanchang 28
Jakarta 27
Turku 27
Dong Ket 26
Rio de Janeiro 25
Turin 25
Montreal 24
Ottawa 24
Shenyang 24
London 23
Tokyo 23
Tianjin 22
Guangzhou 21
Johannesburg 21
Chennai 20
Columbus 19
Hebei 18
Jinan 18
Tashkent 18
Warsaw 18
Andover 17
Da Nang 17
Phoenix 17
Poplar 17
Denver 16
Jiaxing 16
Zhengzhou 16
Changsha 15
Dhaka 15
Tampa 15
Brooklyn 14
Haiphong 14
Mumbai 14
Nuremberg 14
Stockholm 14
Atlanta 13
Baghdad 13
Boston 12
Indianapolis 12
Belo Horizonte 11
Brasília 11
Campinas 11
Huizen 11
Quito 11
Addis Ababa 10
Biên Hòa 10
Curitiba 10
Desio 10
Hải Dương 10
Mexico City 10
Pune 10
San Francisco 10
Totale 11.323
Nome #
Hepcidin regulation in a mouse model of acute hypoxia 591
Phenotypic heterogeneity in seven Italian cases of aceruloplasminemia 446
GNPAT rs11558492 is not a major modifier of iron status: Study of Italian hemochromatosis patients and blood donors 410
A severe hemojuvelin mutation leading to late onset of HFE2-hemochromatosis 383
Hif1a: A putative modifier of hemochromatosis 382
Idiopathic erythrocytosis: a germline disease? 381
Prolonged exposure to welding fumes as a novel cause of systemic iron overload 349
Inherited iron overload disorders 346
Type 3 hemochromatosis and beta-thalassemia trait 341
Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2 336
Genetic and metabolic factors are associated with increased hepatic iron stores in a selected population of p.Cys282Tyr heterozygotes 336
Hepcidin regulation in a mouse model of acute hypoxia 336
Transferrin receptor 2 mutations in patients with juvenile hemochromatosis phenotype 331
Novel mutations of the ferroportin gene (SLC40A1): Analysis of 56 consecutive patients with unexplained iron overload 329
Unexplained isolated hyperferritinemia without iron overload 324
Circulating factors are involved in hypoxia-induced hepcidin suppression 318
Atypical phenotype in a patient with ceruloplasmin mutations in the compound heterozygous state 309
Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload 301
Heterogeneity of iron overload: Clinical, biochemical, histopathologic and genetic study of 70 patients 298
CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients 295
Dysmetabolic Hepatic Iron Overload Syndrome: Analysis of Hepcidin Response to Acute Oral Iron and Chronic Iron Overload 294
Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with HFE-related hemochromatosis 294
Does aceruloplasminemia modulate iron phenotype in thalassemia intermedia? 290
Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome 280
Hepcidin expression in iron overload diseases is variably modulated by circulating factors 280
Ferroportin disease: A novel SLC40A1 mutation 280
A time course of hepcidin response to oral iron challenge in hfe and tfr2 hemochromatosis patients 274
UNEXPLAINED ISOLATED HYPERFERRITINEMIA IN PATIENTS WITHOUT MUTATIONS IN FERRITIN GENE AND L-FERRITIN IRES REGIONS 272
IRON AND HYPOXIA LINK: DOWNREGULATION OF LUCIFERASE ACTIVITY OF HEPCIDIN PROMOTER BY HYPOXIC SERA IN HUH-7 CELLS 270
HFE and SLC40A1 polymorphisms in patients with unexplained iron overload 269
Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project 268
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 267
Ceruloplasmin variants might have different effects in different iron overload disorders 267
Identification of novel mutations by targeted NGS panel in patients with hyperferritinemia 265
Prevalence of C282Y and E168X HFE mutations in an italian population of northern european ancestry 260
Reduced expression of hepcidin in patients with myelodysplastic syndrome and myelofibrosis: The causes might be more heterogeneous than in thalassaemia 259
Simultaneous liver iron and fat measures by magnetic resonance imaging in patients with hyperferritinemia 257
Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure 255
The iron-hypoxia link: hepcidin has a central role in the response to acute and chronic exposure to hypobaric hypoxia. data from the highcare project 253
Analysis of Polymorphisms of Genes Regulating Hepcidin Transcription in Hfe-Hemochromatosis 251
Patients with chronic hepatitis C may be more sensitive to iron hepatotoxicity than patients with HEF-Hemochromatosis 250
Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders 245
GNPAT rs11558492 is not associated to iron overload in Italian HFE p.C282Y homozygotes 245
Homozygous deletion of HFE: The Sardinian hemochromatosis? 238
Single breath-hold multiecho mri sequences (at 1.5t) for the simultaneous lipid quantification and t2*measurement in patients with increased serum ferritin levels 226
Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation 225
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 224
Angiotensin type 2 and mas receptor activation prevents myocardial fibrosis and hypertrophy through the reduction of inflammatory cell infiltration and local sympathetic activity in angiotensin ii‐dependent hypertension 219
Total iron-overload measurement in the human liver region by the magnetic iron detector. 216
Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis 216
Homozygosity for transferrin receptor-2 y250x mutation induces early iron overload 214
A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis 214
Reference Values of Ceruloplasmin across the Adult Age Range in a Large Italian Healthy Population 212
Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and Inflammation 202
Erythrocytapheresis plus erythropoietin: An alternative therapy for selected patients with hemochromatosis and severe organ damage 198
Interaction Between the PNPLA3 I148M Mutation, Body Weight, And Steatosis, In Determining The Progression To Cirrhosis In Hereditary Hemochromatosis 196
Genome-wide association study identifies TF as a significant modifier gene of iron metabolism in HFE hemochromatosis 195
Hypoxia-dependent hepcidin down-regulation: an in vitro study 189
Hereditary Hyperferritinemia 188
Transferrin Saturation and Serum Ferritin Are Main Predictors of Liver Iron Content in Subjects With Hyperferritinemia 187
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 184
Interaction between the PNPLA3 I148M mutation and body weight in determining steatosis and the progression to cirrhosis in hereditary hemochromatosis 163
Gene symbol: FTL. Disease: Hyperferritinemia-cataract syndrome 140
Molecular testing in hemochromatosis 128
Emerging nanocarrier systems for the enhanced delivery of active pharmaceutical ingredients to the intestine 121
Totale 17.582
Categoria #
all - tutte 54.149
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.149


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021118 0 0 0 0 0 0 0 0 0 0 0 118
2021/2022960 61 93 106 76 70 56 62 51 40 74 81 190
2022/20231.529 205 429 155 156 101 222 10 84 95 10 30 32
2023/2024982 40 48 43 45 107 272 194 50 42 15 18 108
2024/20252.288 122 193 114 91 238 104 132 110 261 374 220 329
2025/20266.877 721 334 473 749 880 372 1.004 271 541 634 454 444
Totale 17.582